A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia

Introduction: Prescribing cascade refers to use of a medication to treat a drug-related adverse event. Prescribing cascades increase medication use, cost, and risk of adverse events. Objective: Our objective was to use administrative health data to identify whether use of medications from the anticholinergic cognitive burden scale was associated with proton pump inhibitor (PPI) prescribing consistent with a prescribing cascade in older adults with dementia. Method: The cohort was comprised of Nova Scotia Seniors’ Pharmacare beneficiaries identified to have dementia and medication dispensation data recorded between 1 April 2010, or cohort entry and 31 March 2015. Anticholinergic medications from the anticholinergic cognitive burden scale (ACB) were abstracted. A look back period of 365 days identified if a PPI had been dispensed preceding anticholinergic dispensation. PPI initiation within 30, 60, 90, or 180 days of the anticholinergic medication was assessed. Demographic description of those dispensed anticholinergic medications or PPIs were reported. Risk factors for the prescribing cascade were investigated with logistic regression and Cox proportional hazards modelling including a sex-stratified analysis. Results: We identified 28,952 Nova Scotia Seniors’ Pharmacare beneficiaries with dementia and prescription dispensation data. Anticholinergic medications were frequently dispensed with 63.4% of the cohort dispensed at least one prescription for an anticholinergic medication. The prescribing cascade defined as up to 180-days between anticholinergic medication inititation and PPI dispensation, occurred in 1,845 Nova Scotia Seniors’ Pharmacare beneficiaries with dementia (incidence 6.4%). Multivariate regression showed those experiencing the prescribing cascade after initiating any anticholinergic were younger (OR 0.98, 95%CI [0.97–0.98]), less likely to live in an urban location (OR 0.82, 95%CI [0.74–0.91]), or to be men (OR 0.74, 95%CI [0.67–0.82]). Cox regression demonstrated an increased risk of starting a PPI within 180 days when initiating any medication from the ACB (HR 1.38, 95%CI [1.29–1.58]). Discussion: Regression modelling suggested that anticholinergic medications increased the risk of PPI dispensation consistent with a prescribing cascade in the cohort. The identification of the prescribing cascade in this population of older Nova Scotia Seniors’ Pharmacare Program beneficiaries with dementia using administrative health data highlights how routinely collected health data can be used to identify prescribing cascades.

[1]  W. Peetermans,et al.  Cost-effectiveness of check of medication appropriateness: methodological approach , 2022, International Journal of Clinical Pharmacy.

[2]  J. Debes,et al.  Assessment of proton-pump inhibitor use, race, socioeconomic status, and mortality in individuals with COVID-19. , 2021, European journal of gastroenterology & hepatology.

[3]  J. Turgeon,et al.  Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models , 2021, Drugs & Aging.

[4]  E. McArthur,et al.  The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications , 2021, Neurourology and urodynamics.

[5]  C. Ohyama,et al.  The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan , 2021, International Urology and Nephrology.

[6]  S. Hsieh,et al.  Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study , 2021, Journal of personalized medicine.

[7]  A. Ford,et al.  Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials , 2021, British journal of clinical pharmacology.

[8]  R. Stewart,et al.  Centrally Acting Anticholinergic Drugs Used for Urinary Conditions Associated with Worse Outcomes in Dementia. , 2021, Journal of the American Medical Directors Association.

[9]  A. Rezapour,et al.  A Systematic Review of Potentially Inappropriate Medications Use and Related Costs Among Elderly. , 2021, Value in health regional issues.

[10]  T. Stürmer,et al.  Effects of anticholinergic and sedative medication use on fractures: A self‐controlled design study , 2021, Journal of the American Geriatrics Society.

[11]  G. Onder,et al.  The Association of Anticholinergic Drugs and Delirium in Nursing Home Patients With Dementia: Results From the SHELTER Study. , 2021, Journal of the American Medical Directors Association.

[12]  Umut Yener Kara,et al.  Long-Term Proton Pump Inhibitor Use is a Risk Factor for Mortality in Patients Hospitalized for COVID-19. , 2021, Turkish journal of medical sciences.

[13]  K. Higuchi,et al.  Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin , 2021, European Journal of Clinical Pharmacology.

[14]  E. Manias,et al.  Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis , 2021, British journal of clinical pharmacology.

[15]  Y. Bao,et al.  Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis , 2021, Neuroscience & Biobehavioral Reviews.

[16]  K. Bhaskaran,et al.  Proton pump inhibitors and risk of all‐cause and cause‐specific mortality: A cohort study , 2021, British journal of clinical pharmacology.

[17]  L. Dolovich,et al.  The Evolving Role and Impact of Integrating Pharmacists into Primary Care Teams: Experience from Ontario, Canada , 2020, Pharmacy.

[18]  M. Schnitzer,et al.  Trends in Prescribing Patterns of Proton Pump Inhibitors Surrounding New Guidelines. , 2020, Annals of epidemiology.

[19]  H. Goyal,et al.  Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19 , 2020, European journal of gastroenterology & hepatology.

[20]  Kyungdo Han,et al.  Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease , 2020, BMC Geriatrics.

[21]  B. Farrell,et al.  Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study , 2020, BMC Geriatrics.

[22]  P. Ungprasert,et al.  Use of proton pump inhibitors is associated with a higher risk of pneumonia in cirrhotic patients: a systematic review and meta-analysis , 2020, Annals of gastroenterology.

[23]  T. Manini,et al.  Evaluation of the Potential Acetylcholinesterase Inhibitor‐Induced Rhinorrhea Prescribing Cascade , 2020, Journal of the American Geriatrics Society.

[24]  Kyungdo Han,et al.  Metoclopramide and Levosulpiride Use and Subsequent Levodopa Prescription in the Korean Elderly: The Prescribing Cascade , 2019, Journal of clinical medicine.

[25]  P. Burns,et al.  Hospitalisation for medication misadventures among older adults with and without dementia: A 5‐year retrospective study , 2019, Australasian journal on ageing.

[26]  J. Helenius,et al.  Acid-suppressive medications and risk of pneumonia in acute stroke patients: A systematic review and meta-analysis , 2019, Journal of the Neurological Sciences.

[27]  Wen-Chuan Lin,et al.  Association of Increased Risk of Pneumonia and Using Proton Pump Inhibitors in Patients With Type II Diabetes Mellitus , 2019, Dose-response : a publication of International Hormesis Society.

[28]  P. Rochon,et al.  Assessing the Scope and Appropriateness of Prescribing Cascades , 2019, Journal of the American Geriatrics Society.

[29]  R. Khoury,et al.  Rational deprescribing in the elderly. , 2019, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[30]  Chien-Chang Lee,et al.  Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta‐analysis of randomized controlled trials and observational studies , 2019, Expert opinion on drug safety.

[31]  L. Fratiglioni,et al.  Risk Factors for Injurious Falls in Older Adults: The Role of Sex and Length of Follow‐Up , 2018, Journal of the American Geriatrics Society.

[32]  P. Rochon,et al.  What Is Known About Preventing, Detecting, and Reversing Prescribing Cascades: A Scoping Review , 2018, Journal of the American Geriatrics Society.

[33]  M. Olsen,et al.  An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade. , 2018, Journal of the American Pharmacists Association : JAPhA.

[34]  D. Scott,et al.  The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors , 2017, Current Gastroenterology Reports.

[35]  P. Rochon,et al.  The prescribing cascade revisited , 2017, The Lancet.

[36]  P. Moayyedi,et al.  Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. , 2017, Canadian family physician Medecin de famille canadien.

[37]  P. Moayyedi,et al.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults. , 2017, The Cochrane database of systematic reviews.

[38]  M. Dramé,et al.  Risk Factors for Adverse Drug Reactions in Older Subjects Hospitalized in a Dedicated Dementia Unit. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[39]  Mohammad Rababa,et al.  Proton Pump Inhibitors and the Prescribing Cascade. , 2016, Journal of gerontological nursing.

[40]  P. Nishtala,et al.  Anticholinergics: theoretical and clinical overview , 2016, Expert opinion on drug safety.

[41]  J. Long,et al.  A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. , 2015, British journal of clinical pharmacology.

[42]  J. Beauchamp,et al.  Proton Pump Inhibitors (PPI) , 2015 .

[43]  S. Duffull,et al.  Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review , 2015, BMC Geriatrics.

[44]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[45]  M. Boustani,et al.  Impact of anticholinergics on the aging brain: a review and practical application , 2008 .

[46]  R. McGlinchey,et al.  The anticholinergic risk scale and anticholinergic adverse effects in older persons. , 2008, Archives of internal medicine.

[47]  I. Forgacs,et al.  Overprescribing proton pump inhibitors , 2008, BMJ : British Medical Journal.

[48]  David L Streiner,et al.  A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. , 2005, Archives of internal medicine.

[49]  H. Beijer,et al.  Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies , 2002, Pharmacy World and Science.

[50]  P. Rochon,et al.  Drug therapy , 1995, The Lancet.

[51]  B. Santos-Ramos,et al.  Systematic review on the use of anticholinergic scales in poly pathological patients. , 2016, Archives of gerontology and geriatrics.